Indication of EGFR Kinase Inhibitors Should Be Refined

Česká verzia

Authors: P. Heneberg
Authors place of work: 3. lékařská fakulta Univerzity Karlovy, Praha
Published in the journal: Klin Onkol 2011; 24(2): 87-93
Category: Reviews

Summary

Even though lung cancer incidence began to decline in the majority of industrialized countries, is still belong to cancers with one of the highest incidence and mortality rates. In the Czech Republic, epidermal growth factor receptor (EGFR) kinase activity inhibitors erlotinib and gefitinib are approved for the use as the second- and third-line treatment of non-small-cell lung cancer. In a cohort of non-small-cell lung cancer patients, erlotinib administration led to tumour regression in less than 20% of patients. However, when used in patients with EGFR-activating mutations, e. g. L858R or delE746-A750, the response rate increased to 75–82% in several parallel clinical studies. Similarly, improved response rate was reported in patients bearing amplified wild-type EGFR gene. In contrary, patients with T790M, D761Y, L747S, and T854A mutations (and some other rare abberations) were found to be resistant to treatment with small-molecule inhibitors targeting the active site of the kinase domain. These mutations do not change the EGFR affinity to gefitinib or erlotinib but the mutated receptor is able to bind ATP into its active site even in the presence of erlotinib or gefitinib, similar to a wild-type receptor without an inhibitor. Besides that, when the EGFR molecule bears both the activating (e. g. L858R) and resistance-inducing mutation (e. g. T790M), the tumour acquires resistance to both erlotinib and gefitinib treatment. Currently, research focuses on a development of new strategies that would allow treatment of patients bearing mutations inducing resistance to the small-molecule inhibitors targeted on the active site of EGFR kinase domain. Contrary to the current guidelines for Czech oncologists, identification of EGFR with any of the above mentioned resistance-inducing somatic mutations should be considered as an explicit contraindication for non-small-cell cancer treatment using small-molecule EGFR kinase activity inhibitors erlotinib or gefitinib. This should also include patients in whom a resistance-inducing mutation is detected together with any of the activating mutations or deletions.

Key words:
adenocarcinoma – lung cancer – protein kinase inhibitors – antitumor agents – genetic predisposition to disease – neoplastic process – genetic markers – pharmacological biomarkers

Zdroje

1. Zásady cytostatické léčby maligních onkologických onemocnění. Česká onkologická společnost ČLS JEP, Česká republika. 11. vydání [aktualizováno 1. srpna 2010; citováno 4. října 2010]. Dostupné z: http://www.linkos.cz/odbornici/info_praxe/standardy.php? t=1.

2. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290(16): 2149–2158.

3. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21(12): 2237–2246.

4. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496): 1527–1537.

5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123–132.

6. Lee DH, Han JY, Yu SY et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006; 1(9): 965–971.

7. Zatloukal P. Cílená léčba nemalobuněčného karcinomu plic (NSCLC). Medical Tribune 2010; 6 [aktualizováno 28. března 2010; citováno 4. října 2010]. Dostupné z: http://www.tribune.cz/clanek/17123.

8. Hajdúch M. Mutace genů EGFR1 a KRAS. In: V. dny diagnostické, prediktivní a experimentální onkologie & II. sympózium o cílené biologické léčbě, 25.–27. 11. 2009, Olomouc. Onkologie 2009; 3 (Suppl B): 11–12.

9. Svoboda M, Fabian P, Slabý O et al. Cílená léčba bronchioloalveolárního plicního adenokarcinomu inhibitory tyrozinkinázové aktivity EGFR: kazuistika klinicky promptní a výrazné odpovědi a přehled literatury. Klin Onkol 2010; 23(4): 224–230.

10. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129–2139.

11. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497–1500.

12. Asahina H, Yamazaki K, Kinoshita I et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95(8): 998–1004.

13. Sutani A, Nagai Y, Udagawa K et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006; 95(11): 1483–1489.

14. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24(21): 3340–3346.

15. Sunaga N, Tomizawa Y, Yanagitani N et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007; 56(3): 383–389.

16. Paz-Ares L, Sanchez JM, Garcia-Velasco A et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). ASCO Meeting Abstract 20. 6. 2006. J Clin Oncol 2006; 24 (Suppl 18): 7020.

17. Shepherd FA, Tsao MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006; 24(7): 1219–1220.

18. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinoma to gefitinib or erlotinib. PLoS Med 2005; 2(1): e17.

19. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22(5): 785–794.

20. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22(5): 777–784.

21. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25(12): 15451–552.

22. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non--small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892–5899.

23. Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64(15): 5355–5362.

24. Preston GG, Calvo E, Papadopoulos K et al. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors. ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 3005.

25. Baselga J, Schoffski P, Rojo F et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 3006.

26. Naret CL, Ramalingam S, Beattie L et al. Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 17045.

27. Guy SP, Ashton S, Hughes G et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular targeting agent ZD6126 in human colorectal cancer models. Clin Cancer Res 2003; 9: 6143.

28. Fehrenbacher L, O’Neill V, Belani CP et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 7062.

29. Natale RB, Bodkin S, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 7000.

30. Heymach JV, Johnson BE, Prager DE et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 7016.

31. Pao W, Miller WA, Politi KA et al. Acquired resiteance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2(3): e73.

32. Kobayashi S, Boggon TJ, Dayram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352(8): 786–792.

33. Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462(7276): 1070–1074.

34. Jančaříková D, Pešek M, Benešová L et al. Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M. Anticancer Res 2007; 27(4A): 1879–1882.

35. Li D, Shinamura T, Ji H et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12(1): 81–93.

36. Besse B, Eaton KD, Soria JC et al. Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Presented at the 20th Annual EORTC-NCI-AACR Symposium, Geneva, Switzerland 2008, abstract 203.

37. Ercan D, Zejnullahu K, Yonesaka K et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29(16): 2346–2356.

38. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827): 1039–1043.

39. Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007; 13(6): 675–677.

40. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17(1): 77–88.

41. Yoshida T, Okamoto I, Okamoto W et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2010; 101(1): 167–172.

42. Okamoto W, Okamoto I, Tanaka K et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9(10): 2785–2792.

43. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118(7): 2609–2619.

44. Sholl LM, Xiao Y, Joshi V et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010; 133(6): 922–934.

45. Jänne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 2008; 60 (Suppl 2): S3–S9.

46. Dziechciarková M, Berkovcová J, Trojanec R et al. Využití laserové mikrodisekce pro přípravu komplexních vzorků z nádorové tkáně pro účely mikrogenomických analýz. Klin Onkol 2007; 20: 323–329.

47. Dziechciarková M, Berkovcová J, Trojanec R et al. Využití laserové mikrodisekce pro přípravu komplexních vzorků z nádorové tkáně pro účely mikrogenomických analýz. Klin Onkol 2006; 19 (Suppl): 355–360.

48. Mendoza L. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update. Klin Onkol 2009; 22(4): 131–138.

49. Berkovcová J, Hajdúch M, Dziechciarková M et al. Predikce účinnoti tyrozinkinázových inhibitorů EGFR1 v léčbě nemalobuněčných plicních karcinomů. Klin Onkol 2006; 19(3): 171–176.

50. Wingo PA, Cardinez CJ, Landis SH et al. Long-Term Trends in Cancer Mortality in the United States, 1930–1998. Cancer 2003; 97 (Suppl 12): 3133–3275.

51. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice, verze 7.0. Masarykova univerzita, Brno, ČR 2007 [aktualizováno 14. ledna 2011; citováno 14. ledna 2011]. Dostupné z: http://www.svod.cz.